Cerwinka Wolfgang H, Scherz Hal C, Kirsch Andrew J
Children's Healthcare of Atlanta, Emory University School of Medicine, 5445 Meridian Mark Road, Suite 420, Atlanta, GA 30342, USA.
Adv Urol. 2008;2008:513854. doi: 10.1155/2008/513854.
The goal of this review is to present current indications, injectable agents, techniques, success rates, complications, and potential future applications of endoscopic treatment for vesicoureteral reflux (VUR) in children.
The endoscopic method currently achieving one of the highest success rates is the double hydrodistention-implantation technique (HIT). This method employs dextranomer/hyaluronic acid copolymer, which has been used in pediatric urology for over 10 years and may be at present the first choice injectable agent due to its safety and efficacy.
While most contemporary series report cure rates of greater than 85% for primary VUR, success rates of complicated cases of VUR may be, depending on the case, significantly lower. Endoscopic treatment offers major advantages to patients while avoiding potentially complicated open surgery. As the HIT method continues to be applied to complex cases of VUR and more outcome data become available, the indication for endoscopic treatment may exceed the scope of primary VUR.
Endoscopic injection is emerging as the treatment of choice for VUR in children.
本综述的目的是介绍儿童膀胱输尿管反流(VUR)内镜治疗的当前适应证、可注射药物、技术、成功率、并发症以及潜在的未来应用。
目前成功率最高的内镜方法之一是双重水扩张-植入技术(HIT)。该方法采用葡聚糖omer/透明质酸共聚物,其已在小儿泌尿外科使用超过10年,由于其安全性和有效性,目前可能是首选的可注射药物。
虽然大多数当代系列报道原发性VUR的治愈率超过85%,但VUR复杂病例的成功率可能因病例而异,显著较低。内镜治疗为患者提供了主要优势,同时避免了潜在的复杂开放手术。随着HIT方法继续应用于VUR复杂病例且更多结果数据可用,内镜治疗的适应证可能会超出原发性VUR的范围。
内镜注射正成为儿童VUR的首选治疗方法。